Novo Nordisk A/S (NYSE:NVO) Rating Increased to Hold at Zacks Research

Novo Nordisk A/S (NYSE:NVO) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other research firms have also issued reports on NVO. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Berenberg Bank set a $47.00 price target on Novo Nordisk A/S in a report on Wednesday. Finally, Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Four research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus price target of $64.94.

Novo Nordisk A/S Stock Down 1.4%

NVO stock opened at $46.52 on Tuesday. The stock has a fifty day moving average of $47.24 and a 200-day moving average of $44.61. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The company has a market capitalization of $207.71 billion, a price-to-earnings ratio of 11.37, a PEG ratio of 4.30 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. As a group, equities research analysts predict that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NVO. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $25,000. Scarborough Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $26,000. WealthCollab LLC boosted its position in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares in the last quarter. Jackson Grant Investment Advisers Inc. bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $29,000. Finally, Quaker Wealth Management LLC lifted its stake in shares of Novo Nordisk A/S by 186.0% in the 4th quarter. Quaker Wealth Management LLC now owns 615 shares of the company’s stock worth $31,000 after purchasing an additional 400 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market is unlikely to be “winner-take-all,” arguing that patients will seek differentiated treatments, including pills. This supports Novo’s ability to compete beyond its current injectable products. Reuters article
• Positive Sentiment: Oral Wegovy prescriptions reportedly reached a record, while management sees a long runway for GLP-1 adoption as obesity remains widespread and treatment could eventually reduce healthcare costs. Fox Business article
• Positive Sentiment: Novo’s once-weekly basal insulin Awiqli is now available in the United States, adding a commercial opportunity in diabetes care beyond the obesity franchise. Awiqli availability article
• Neutral Sentiment: Erste Group raised its FY2026 EPS estimate to $3.27 from $3.20, although that remains below the broader consensus estimate of $3.39. Erste Group estimate article
• Negative Sentiment: Berenberg downgraded NVO from “buy” to “hold,” saying much of the anticipated Wegovy-pill upside is already reflected in the valuation and that the stock’s multiple may revert toward the European pharmaceutical average. Berenberg downgrade article
• Negative Sentiment: Management acknowledged that Eli Lilly is gaining market share. Investors remain concerned about flat Wegovy sales, pricing pressure, pipeline setbacks and Lilly’s competitive position in oral obesity treatments. BeInCrypto article
• Negative Sentiment: Novo is defending a lawsuit against Lilly over weight-loss-drug advertising. Although the company says competition must be fair, the litigation adds uncertainty and could distract from the commercial battle. CNBC article

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.